SIMCOR tablets contain niacin extended-release (NIASPAN) and simvastatin in combination. Simvastatin, an inhibitor of HMG-CoA reductase, and niacin are both lipid-altering agents. Niacin Extended-Release is an extended release form of nicotinic acid, or 3-pyridinecarboxylic acid.
SIMCOR (simvastatin/niacin) is indicated for the following:
Patients with Hypercholesterolemia Requiring Modifications of Lipid Profiles
SIMCOR is indicated to reduce total-C, LDL-C, Apo B, non-HDL-C, or TG, or to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb) when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate.
SIMCOR is indicated to reduce TG in patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia) when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate.
Limitations of use
No incremental benefit of SIMCOR on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin monotherapy and niacin monotherapy has been established.
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
Published Studies Related to Simcor (Simvastatin / Niacin)
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. [2011.05]
BACKGROUND: Efforts to lower plasma lipid levels sometimes require multiple agents with different mechanisms of action to achieve results specified by national treatment guidelines... CONCLUSION: There is a small pharmacokinetic drug interaction between ER niacin and ezetimibe/simvastatin and although this is not considered to be clinically significant, the concomitant use of these drugs should be appropriately monitored, especially during the niacin titration period.
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. [2010.11.24]
OBJECTIVE: To compare the effects of combination niacin extended-release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analysis from SUPREME, a study which compared the lipid effects of niacin extended-release + simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia... CONCLUSION: NER/S treatment significantly improved apo A-I levels and the apo B:A-I ratio, significantly lowered the number of atherogenic LDL particles and VLDL and chylomicron particles, and increased the mean size of LDL and VLDL particles, compared with atorvastatin.
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010.02.15]
The safety and efficacy of combination ezetimibe/simvastatin (E/S) plus extended-release niacin was assessed in 942 patients with type IIa/IIb hyperlipidemia for 64 weeks in a randomized, double-blind study. Patients received E/S (10/20 mg) plus niacin (to 2 g) or E/S (10/20 mg) for 64 weeks, or niacin (to 2 g) for 24 weeks and then E/S (10/20 mg) plus niacin (2 g) or E/S (10/20 mg) for an additional 40 weeks...
Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. [2009.04]
BACKGROUND: Niacin has multiple lipoprotein effects that may provide cardiovascular benefit when added to statin monotherapy... CONCLUSIONS: We demonstrate that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high-dose simvastatin, while also raising HDL-cholesterol. Results of large clinical trials will inform whether niacin-statin combinations reduce cardiovascular disease events.
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). [2008.05.15]
The efficacy and safety of 2 regimens of a combination of a proprietary niacin extended release plus simvastatin (NER/S; 1,000/20 and 2,000/20 mg/day) were compared with simvastatin monotherapy (20 mg/day) for 24 weeks in 319 high-risk patients with predominantly mixed dyslipidemia who were already at National Cholesterol Education Program Adult Treatment Panel III risk-adjusted goals for low-density lipoprotein cholesterol...
Clinical Trials Related to Simcor (Simvastatin / Niacin)
Effect of Simvastatin on Cardiac Function [Recruiting]
It is well know that statins have been used to low cholesterol to prevent and treat coronary
artery disease for many years. It was also reported that statins could protect endothelial
function and cardiac function during coronary artery bypass graft. However, some results
were controversial. Also, there is no clinical data available on statin cardiac protection
during surgery in China where rheumatic heart disease is prevalent. Thus, the investigators
are trying to see whether statins can protect heart injury during cardiac surgery in
Chinese. Part of patients will receive statin treatment and part of will not before surgery
in the study. Both patients' heart function will be measured and compared after surgery to
determine whether statins can protect heart injury during heart surgery.
Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery [Recruiting]
Statins have been used to low cholesterol to prevent and treat coronary artery diseases. It
was also reported that statins could protect endothelial function and cardiac function
during coronary artery bypass graft. We recent found simvastatin reduced myocardial injury
during noncoronary artery cardiac surgery in single medical center. We further investigate
that whether simvastatin can protect myocardium during noncoronary artery cardiac surgery
with cardiopulmonary bypass and improve cardiac function with long term use postoperatively
in two medical centers.
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (â¥ 200 and < 500 mg/dL) [Recruiting]
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared
to placebo in lowering high fasting triglyceride levels in patients with high risk for
cardiovascular disease and fasting triglyceride levels ≥ 200 and < 500 mg/dL.
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. [Recruiting]
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic
acid (EPA) being developed by Amarin Pharma Inc. for the treatment of hypertriglyceridemia.
The purpose of this study is to evaluate whether this drug, combined with a statin therapy,
will be superior to the statin therapy alone, when used as a prevention in reducing
long-term cardiovascular events in high-risk patients with mixed dyslipidemia.
Reports of Suspected Simcor (Simvastatin / Niacin) Side Effects
Feeling Hot (207),
Skin Burning Sensation (110),
Burning Sensation (65),
Blood Glucose Increased (54),
Myalgia (41), more >>
Page last updated: 2011-12-09